Tag: Dystrophy
Failure of Pfizer against Duchenne muscular dystrophy
(AOF) – Pfizer announced the failure of Ciffreo, a global phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating fordadistrogen movaparvovec, its investigational mini-dystrophin gene therapy, in patients ambulatory patients with…
Biophytis presented the potential of RuvembriTM in the treatment of Duchenne muscular dystrophy – 03/08/2024 at 07:00
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative…
Bayer: Testing a treatment for muscular dystrophy
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Biophytis presents the development of Sarconeos (BIO101) as a drug candidate in rare neuromuscular diseases at the Muscular Dystrophy Association (MDA) clinical and scientific conference – 03/20/2023 at 08:00
Paris (France), Cambridge (Massachusetts, United States)), March 20, 2023, 8:00 a.m. CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a biotechnology company specializing in…
Scheuermann’s disease: symptoms, evolution, treatment of spinal dystrophy of growth: Femme Actuelle Le MAG
Scheuermann’s disease: symptoms, evolution, treatment of spinal dystrophy of growth: Femme Actuelle Le MAG Path 2 645DBCB3-7979-441A-BA4B-98E7BF17E1BE 1785B508-2A96-4CF5-AA87-79B0FE0441BF advertisement source site-44